VIETNAM’S PHARMACEUTICAL MARKET REACHES $7B

The total value of Vietnam’s pharmaceutical market is estimated at US$7 billion, but the industry faces challenges including low infrastructure and limited financial capacity, insiders have said.

Vietnam’s pharmaceutical industry has experienced high growth over the past 10 years, with a compound annual growth rate of 7.3%.

According to the Drug Administration of Vietnam under the Ministry of Health, the current Vietnamese pharmaceutical market is approximately $7 billion, with an average drug consumption of $70 per capita, a 10-fold increase compared to 2000, Le Van Truyen, Chairman of the ministry’s Advisory Council for the issuance of the Certificate of Registration of Drugs-Medicinal Ingredients announced during a seminar in Hanoi on Wednesday.

Vietnam is currently among the countries with the highest total value of the pharmaceutical market and fastest industry growth worldwide. The total value of Vietnam’s pharmaceutical market reached $2.7 billion in 2015, increased to $5.1 billion in 2018, and $6.1 billion in 2020.

According to the World Health Organization (WHO) classification, Vietnam’s pharmaceutical industry is at level 3, which means it has a domestic pharmaceutical industry, generic drug production, and the ability to export some pharmaceuticals.

“However, Vietnam’s pharmaceutical industry is facing many challenges and difficulties as the country increasingly integrates into the global economy,” said Truyen.

Vietnam currently has only 17 out of 250 factories meeting the Advanced Good Manufacturing Practice (GMP), a WHO system for ensuring that products are consistently produced and controlled according to quality standards and more than 200 meet the GMP standards.

Vietnam also lacks centralized pharmaceutical-industrial zones with an ecosystem that includes: research and development centers, bioavailability-bioequivalence testing facilities, clinical trial facilities, testing facilities, pharmaceutical production plants, packaging manufacturing plants, and related service centers specifically for the pharmaceutical industry, he said.

In terms of financial capacity, most domestic pharmaceutical companies are small-scale with low revenues, and there are no large-scale national pharmaceutical corporations. Financial resources for new investments are very limited.

Digital transformation is also a significant challenge for Vietnamese pharmaceutical companies in the context of the ongoing 4.0 industrial revolution.

Regarding those challenges, Truyen suggested the need for strong investment policies in infrastructure and enhancing the production capacity of existing pharmaceutical factories. At the same time, preferential treatments should be provided to pharmaceutical companies to build and develop new factories, particularly for biological/biosimilar drug production.

Vietnam’s pharmaceutical industry is considered a key industry that requires concentrated resources for strong development. Vietnam aims to become a high-value pharmaceutical manufacturing center in the region by 2030, with the value of domestically produced drug exports reaching about $1 billion.

Source: VNExpress

About STELLAPHARM

Stellapharm J.V. Co., Ltd. is currently known as one of leading generics pharmaceutical companies and strong manufacturers in Vietnam. Established in 2000, Stellapharm was built on the foundation of a manufacturing factory in Vietnam and formed a joint venture with a partner from Germany. We focus on both prescription drugs and non-prescription especially in cardiovascular diseases, anti-diabetics drugs, etc. Products of Stellapharm are now used by millions of patients in more than 50 countries worldwide.

The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.

Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An City, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com

You May like

27 Jun 2024

REVISED LAW PROPOSES SWEEPING CHANGES TO PHARMACEUTICAL INDUSTRY

  The version grants pharmaceutical business licenses to non-profit pharmaceutical entities that engage in commercial activities to ensure essential medicines reach a wider range of the population. HÀ NỘI — A revised version of the Law on Pharmaceuticals 2016 will be presented to the National Assembly for discussion and feedback during a legislative meeting from

19 Jun 2024

PANORAMA AND TRENDS OF THE GLOBAL PHARMACEUTICAL MARKET

With the development of the global economy, the growth of the total population and the aging of society, the demand for drugs is increasing, and the market size of the global pharmaceutical industry will maintain growth. stable.In 2023, the total global pharmaceutical market is estimated to be approximately US$1,6 trillion. This is an increase of

03 Jun 2024

AMENDED LAW ON PHARMACY 2016 EXPECTED TO GIVE BETTER ACCESS TO MEDICATION

Despite answering a number of state management requirements, the Pharmacy Law 2016 still displays certain inadequacies. Its amendments are supposed to provide patients with better access to new medication. To address inadequacies in the Law on Pharmacy 2016, the Government has already submitted a draft Law on Amendments for the Pharmacy Law 2016 to the

31 May 2024

PROMOTING VIETNAMESE PHARMACEUTICAL INDUSTRY

Vietnamese pharmaceutical market grew from $2.7 billion in 2015 to $7 billion in 2022 and is forecast to reach more than $10 billion by 2026. The Vietnamese pharmaceutical industry is seeing great advantages.People’s spending on health was increasingly high giving pharmaceutical enterprises great potential for development, said Associate Professor, PhD. Lê Văn Truyền, former Deputy

26 Jan 2024

VIETNAM’S PHARMACEUTICAL INDUSTRY SETS DEVELOPMENT TARGETS FOR THE NEXT DECADE

By 2030, Vietnam will become a center for manufacturing or processing of, and transfer of technologies for, brand-name medicines in the ASEAN region. Under Prime Minister Decision 1165/QD-TTg, approving the National Strategy for development of the domestic pharmaceutical industry through 2030, with a vision toward 2045, it is expected that the domestic pharmaceutical industry’s production